Divergence Neuro

Divergence Neuro operates at the intersection of digital mental health, neurofeedback, clinical analytics, and psychedelic research. Its offering is broader than a standalone EEG hardware product: the company describes a cloud-based platform for therapists and coaches, remote session delivery, assessment workflows, progress tracking, and biomarker-oriented research. The product set includes therapist and coach neurofeedback platforms, TheraQ Assessments, devices, an employee wellness solution, and the NMI Protocol Suite. This gives Divergence a potential position across clinical care, practitioner enablement, and research services, although the available profile does not establish commercial scale, regulatory clearances, or customer adoption. Relative to general mental-health software providers, the differentiator is the integration of EEG-based neurofeedback and biofeedback modalities such as HRV, respiration, skin temperature, and skin conductance. Relative to neurotechnology vendors, the platform emphasizes remote care workflows, questionnaires, clinical analytics, and practitioner tools. Its 2021 relationship with Entheon also indicates relevance to biomarker validation for psychedelic therapies.

Divergence Neuro was founded in 2020 and recorded one Pre Seed funding round on Oct 3, 2020, but the amount and investor identities are undisclosed. The company’s trajectory appears to have developed through product breadth and research partnerships rather than a publicly visible sequence of financing milestones. Its platform has expanded beyond core neurofeedback delivery to include remote assessments, live session streaming, customizable EEG protocols, biofeedback and HRV training, mobile applications, and clinical analytics. The 2021 appointment of Dr. Sergio R. Pérez Rosal as special advisor for clinical and scientific research affairs suggests a push toward stronger clinical validation. The January 2021 partnership with Entheon Biomedical marked a more specific research-commercialization direction, centered on predictive biomarker platform development for psychedelic therapies. The June 2021 appointment of Jeff Moore as COO and board member added operational and governance leadership. Current staffing remains reported in the one-to-ten employee range, and there is no disclosed hiring acceleration, later funding round, or major launch timeline. Consequently, the available evidence supports an early-stage company pursuing multiple adjacent applications, but does not substantiate rapid scale or a clear progression to later-stage commercialization.